Oncology | Phase II Developments | CANADA

Alethia Biotherapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Alethia Biotherapeutics Announces Receipt of FDA Authorization to Begin Phase 2 Development for its EMT Inhibitor, AB-16B5

Lead Product(s): AB-16B5,Docetaxel Trihydrate

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 21, 2020

Details:

Alethia to start a clinical trial of AB-16B5 in combination with docetaxel in subjects with metastatic non-small cell lung cancer who have experienced disease progression following treatment with a platinum-containing doublet treatment and an anti-PD1 or PD-L1.

Theralase Technologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Theralase Receives FDA IND Authorization

Lead Product(s): TLD-1433

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 19, 2020

Details:

Study II utilizes the Therapeutic Dose of the Study Drug (TLD-1433, Theralase's patented PDC), in conjunction with the Study Device (TLC-3200 Medical Laser System) intended to deliver a safe and effective treatment to patients inflicted with BCG-Unresponsive NMIBC.

Theralase Technologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Theralase Provides Company Update on Phase II Bladder Cancer Clinical Study

Lead Product(s): TLD-1433

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 20, 2020

Details:

Enrollment of new patients and conducting the first treatment procedure in the Company's Phase II Non-Muscle Invasive Bladder Cancer clinical study has been temporarily placed on hold.

IMV

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

IMV Announces Breakthrough Data from DeCidE1

Lead Product(s): DPX-Survivac,Cyclophosphamide,Epacadostat

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 25, 2020

Details:

First in-vivo T cell therapy to demonstrate clinical activity in hard-to-treat solid tumor.

IMV

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

IMV to Report Updated Results from DeCidE1, its Ongoing Phase 2 Study of DPX-Survivac for Advanced Recurrent Ovarian Cancer

Lead Product(s): DPX-Survivac

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 20, 2020

Details:

The Phase 2 study is evaluating IMV's lead compound, DPX-Survivac, in patients with advanced recurrent ovarian cancer.

Zymeworks

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Zymeworks Announces Pricing of $279.0 Million Public Offering

Lead Product(s): ZW25

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: J.P. Morgan Securities

Deal Size: $279.0 million Upfront Cash: Undisclosed

Deal Type: MPO January 22, 2020

Details:

The company intends to use the net proceeds to accelerate & expand the global development of ZW25 both as a single agent and in combination with other anti-cancer agents & the clinical development of ZW49.

Zymeworks

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Zymeworks Announces Agreement with Pfizer and Initiation of a New Phase 2 Trial Evaluating ZW25 in Combination with Ibrance® (palbociclib)

Lead Product(s): ZW25,Palbociclib,Fulvestrant

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Pfizer Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement January 12, 2020

Details:

Zymeworks’ HER2-targeted bispecific antibody ZW25 is being evaluated in combination with Pfizer’s Ibrance. Zymeworks will sponsor the study, and Pfizer will provide palbociclib.

Find

Find Oncology Drugs in Phase II Clinical Development in CANADA

Canada

A collaboration with SCORR Marketing

Product Type

Companies

Alethia Biotherapeutics

Alethia Biotherapeutics Announces Receipt of FDA Authorization to Begin Phase 2 Development for its EMT Inhibitor, AB-16B5

Theralase Technologies

Theralase Receives FDA IND Authorization

Theralase Technologies

Theralase Provides Company Update on Phase II Bladder Cancer Clinical Study

IMV

IMV Announces Breakthrough Data from DeCidE1

IMV

IMV to Report Updated Results from DeCidE1, its Ongoing Phase 2 Study of DPX-Survivac for Advanced Recurrent Ovarian Cancer

Zymeworks

Zymeworks Announces Pricing of $279.0 Million Public Offering

Zymeworks

Zymeworks Announces Agreement with Pfizer and Initiation of a New Phase 2 Trial Evaluating ZW25 in Combination with Ibrance® (palbociclib)